What is IGC's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 0.02B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for IGC?

P/E (TTM) is n/a and 52-week range is $0.08 to $0.45 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s IGC figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

What trailing-twelve-month financials does Chartloom show for IGC?

The company profile lists revenue (TTM) near $1M, net income (TTM) near -$913M, EPS (TTM) near -$0.08 when available from the market-data feed. Figures are informational and may lag live markets.

Where is IGC Pharma Inc based, and what identifiers does Chartloom list?

The company context section lists headquarters in Potomac, Maryland, US, 116.1M shares outstanding, ISIN US45408X3089 when available from company profile and filing metadata.

Please enable JavaScript to continue using this application.

IGC Pharma Inc

$IGC

Health Care · Pharmaceuticals

IR Run Scenarios

Overview Charts AI Summary Financials Valuation

Profile

Read AI summary

IGC Pharma, Inc. is a clinical-stage pharmaceutical company that is focused on Alzheimer's disease, developing innovative solutions to address this devastating illness. The company is headquartered in Potomac, Maryland and currently employs 70 full-time employees. The company went IPO on 2006-04-13. The firm's lead asset, IGC-AD1, is a cannabinoid-based therapy is in a Phase 2 trial (CALMA) for agitation in Alzheimer's dementia. The Company’s pipeline includes TGR-63, targeting amyloid plaques, and early-stage programs focused on neurodegeneration, tau proteins, and metabolic dysfunctions. The firm integrates AI to accelerate drug discovery, optimize clinical trials, and enhance patient targeting. The company is also developing a Multimodal Interpretable Transformer for Alzheimer’s Disease (MINT-AD). MINT-AD leverages diverse data sources, including brain scans, genetics, lifestyle, and cognitive metrics, to produce clinically interpretable risk profiles and forecast decline trajectories.

Employees

Website

igcpharma.com/

IPO

2006-04-13

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)

Net income (TTM)

EPS (TTM)

P/E (price / listing EPS)

P/S (TTM)

Forward P/E

Forward P/S

EV / EBITDA

PEG (TTM)

FCF yield (TTM)

Gross margin (TTM)

Net margin (TTM)

Forward revenue growth (NTM)

Dividend / share (TTM)

Dividend yield (TTM)

Payout ratio (TTM)

Dividend growth (5Y)

Company context

Exchange

NYSE MKT LLC

ISIN

US45408X3089

Headquarters

Potomac, Maryland, US

Shares outstanding

116.1M

NAICS sector

Professional, Scientific, and Technical Services

Institutional ownership

22.09%

Browse other companiesFree AI scores and summaries for more stocks